ARRY: To Fill or Not to Fill (the gap), That is the Question

ER tomorrow morning I believe. Here is to a better result than what came to OPK today!

ESMO conference in the next 4 weeks or so where ARRY will be providing updates. Something to mark down on the old calendar...

Which gap?  There is a gap between $10 and $11 too.  Looks like ARRY is backing off resistance at $10 but one has gotta love the 10% jump in the last 3 days.

so do we load up on the ARRY dip here or what?

ARRY down $0.77 to $9.22 today on no news that I found on a 60% increase in share volume as relative strenth drops and the MACD closes.  Looks like a good idea to see if $9 holds.

www.businesswire.com/news/home/20170827005080/en/European-Medicines-Agency-Start-Review-Marketing-Authorization


European Medicines Agency To Start the Review of The Marketing Authorization Applications for Encorafenib and Binimetinib For the Treatment Of BRAF-Mutant Advanced Melanoma
If approved, the combination of encorafenib and binimetinib would represent an important new option for patients with BRAF-mutant advanced, unresectable or metastatic melanoma
The Marketing Authorization Applications are based on the Phase 3 data from the COLUMBUS study demonstrating a significant progression-free-survival (PFS) benefit for the combination of encorafenib and binimetinib compared to vemurafenib (14.9 months versus 7.3 months)

August 28, 2017 02:00 AM Eastern Daylight Time
CASTRES, France--(BUSINESS WIRE)--Pierre Fabre Laboratories the 2nd largest private French pharmaceutical group today announced that the European Medicines Agency (EMA) has validated the review of the Marketing Authorization Applications (MAAs) for the use of the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once daily (COMBO450) for the treatment of patients with BRAF-mutant advanced, unresectable or metastatic melanoma. The submissions are supported by data from the pivotal Phase 3 COLUMBUS study, which showed that patients who received the combination of binimetinib and encorafenib had a significantly longer progression free survival (PFS) compared to patients receiving vemurafenib.

"COLUMBUS results, including progression free survival, objective response rate, dose intensity and tolerability of the combination, provide a strong and consistent theme across multiple endpoints for this study. We are pleased that the EMA has initiated its review of the MAAs of binimetinib and encorafenib. If approved, the combination, co-developed with Array BioPharma, would represent a new and potentially important option for patients with BRAF-mutant advanced melanoma," said Frederic Duchesne, President & CEO Pierre Fabre Pharmaceuticals Division.